Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
How to inject Toujeo (insulin glargine 300U/mL)

How to inject Toujeo (insulin glargine 300U/mL)

Educate your patients on correct injection technique for Toujeo

Switching to Toujeo® (insulin glargine 300 units/mL) from other regimens

Switching to Toujeo® (insulin glargine 300 units/mL) from other regimens

A clinical guide for healthcare professionals on switching patients to Toujeo® (insulin glargine 300 units/mL) from other insulin regimens.

Toujeo: Insulin Naive start Guide

Toujeo: Insulin Naive start Guide

Insulin is one of the most effective glucose-lowering agents for type 2 diabetes and can be titrated to suit an individual patient’s requirements.

Seznam PCSK9i center

Seznam PCSK9i center

V tomto článku se dozvíte, kde najít seznam všech PCSK9i center.

DUPIXENT® - WISSEN kompakt

DUPIXENT® - WISSEN kompakt

Age-Related Risk Factors for IMD: From Infants to Elderly

Age-Related Risk Factors for IMD: From Infants to Elderly

Comprehensive overview of age-specific risk factors for Invasive Meningococcal Disease (IMD), detailing vulnerability patterns across different life stages. Features specific risks for infants, adolescents, and elderly populations, including the impact of maternal antibody decline, nasopharyngeal colonization, and immunosenescence in older adults.

Protecting Pilgrims: Meningococcal Disease Risk Factors During Mass Gatherings

Protecting Pilgrims: Meningococcal Disease Risk Factors During Mass Gatherings

Comprehensive analysis of meningococcal disease risk factors during mass religious gatherings, with focus on the Hajj pilgrimage. Details environmental challenges, demographic vulnerabilities, and transmission dynamics among pilgrims, local residents, and healthcare workers in Mecca, with emphasis on crowded conditions and N. meningitidis carriage rates.

Age and Serogroup Patterns: IMD in South Africa

Age and Serogroup Patterns: IMD in South Africa

Comprehensive analysis of Invasive Meningococcal Disease (IMD) patterns in South Africa, featuring GERMS-SA surveillance data from 2018-2024. Highlights age-specific incidence rates, with detailed focus on infant vulnerability (1.6 per 100,000) and adolescent/young adult peaks. Includes serogroup distribution trends across the country.

Meningococcal Vaccination Impact: Hajj Pilgrimage Case Studies and Global Benefits

Meningococcal Vaccination Impact: Hajj Pilgrimage Case Studies and Global Benefits

Comprehensive analysis of meningococcal vaccine effectiveness during Hajj pilgrimages, featuring case studies from Singapore and Saudi Arabia. Highlights significant reduction in IMD cases post-vaccination and explores the broader benefits of meningococcal conjugate vaccines, including herd immunity and reduced global transmission.

Understanding N. meningitidis: Biology, Serogroups, and Carriage

Understanding N. meningitidis: Biology, Serogroups, and Carriage

Comprehensive overview of Neisseria meningitidis, detailing bacterial characteristics, serogroups, and age-specific carriage patterns. Features evidence from European meta-analysis of 89 studies, highlighting carriage rates from infancy through adulthood and the relationship between carriage and invasive disease.

Clinical Recognition of IMD: Symptoms, Signs, and Presentations

Clinical Recognition of IMD: Symptoms, Signs, and Presentations

Comprehensive guide to clinical presentations of Invasive Meningococcal Disease (IMD), detailing key symptoms of meningitis, meningococcemia, and septic shock. Features diagnostic criteria including fever, headache, photophobia, petechial rash, and less common manifestations such as pneumonia and arthritis. Essential reference for healthcare providers and medical professionals.

IMD Consequences: Mortality, Sequelae, and Long-term Impact

IMD Consequences: Mortality, Sequelae, and Long-term Impact

Comprehensive analysis of Invasive Meningococcal Disease (IMD) outcomes, featuring detailed mortality rates by serogroup and age group, with focus on the 20% survivor sequelae rate. Includes comparative analysis with other vaccine-preventable diseases (VPDs) and highlights the critical 24-hour window for treatment intervention.